BRAIN Biotech AG Sustainability Profile
BRAIN Biotech AG, a leading player in the biotechnology sector, is headquartered in Germany and operates extensively across Europe. Founded in 1997, the company has established itself as a pioneer in the development of innovative bioprocesses and products, particularly in the fields of industrial enzymes and biobased materials. BRAIN Biotech AG offers a unique portfolio of services, including enzyme development and microbial strain optimisation, which cater to various industries such as agriculture, food, and pharmaceuticals. The company is recognised for its commitment to sustainability and efficiency, positioning itself as a key contributor to the circular economy. With a strong market presence and notable achievements in biotechnological advancements, BRAIN Biotech AG continues to drive innovation, making significant strides in enhancing productivity and environmental sustainability across multiple sectors.
DitchCarbon Score
How does BRAIN Biotech AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
BRAIN Biotech AG's score of 28 is lower than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
BRAIN Biotech AG's reported carbon emissions
In 2022, BRAIN Biotech AG reported total carbon emissions of approximately 2,012 kg CO2e, comprising 632.02 kg CO2e from Scope 1 and 1,379.89 kg CO2e from Scope 2 emissions. This marks a significant reduction from 2020, when the company emitted about 1,516,660 kg CO2e, with Scope 1 emissions at 543,860 kg CO2e and Scope 2 emissions at 971,790 kg CO2e. BRAIN Biotech AG has set ambitious climate commitments, aiming for a 30% reduction in Scope 1 and Scope 2 emissions by 2032 compared to their current revenue basis. Additionally, the company is targeting net-zero emissions for both Scope 1 and Scope 2 by 2050. These long-term goals reflect BRAIN Biotech AG's commitment to sustainability and align with industry standards for climate action. The emissions data is not cascaded from any parent organization, indicating that BRAIN Biotech AG is independently reporting its performance and commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2022 | |
|---|---|---|
| Scope 1 | 543,860 | 000.00 |
| Scope 2 | 971,790 | 0,000.00 |
| Scope 3 | - | - |
How Carbon Intensive is BRAIN Biotech AG's Industry?
How Carbon Intensive is BRAIN Biotech AG's Location?
BRAIN Biotech AG's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
BRAIN Biotech AG has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
